Jump to ContentJump to Main Navigation
AMA Manual of Style (10th edition ed.) : A Guide for Authors and Editors

AMA Manual of Style Committee

Publisher:
Oxford University Press
Print Publication Date:
Mar 2007
Print ISBN-13:
9780195176339
Published to AMA Manual of Style:
Apr 2009
DOI:
10.1093/jama/9780195176339.001.0001
© American Medical Association
Contents

Multiple-Drug Regimens

Chapter:
Nomenclature
Author(s):

Margaret A. Winker

15.4.11 Multiple-Drug Regimens

Regimens that include multiple drugs may be referred to by an abbreviation after the nonproprietary names of the drugs have been provided at first mention (see also 15.4.12, Drug Abbreviations, and 14.11, Abbreviations, Clinical, Technical and Other Common Terms). Drug regimens used in oncology frequently are referred to by abbreviations of combinations of antineoplastic agents, but often the abbreviations are not derived from the INNs. For example, the letter O in MOPP is derived from Oncovin, the proprietary name for vincristine sulfate, and the A in ABVD is derived from Adriamycin, the proprietary name for doxorubicin hydrochloride. When the abbreviation is expanded the proprietary names may be provided after the nonproprietary names to clarify the origin of the abbreviation.

The MOPP (methotrexate, vincristine sulfate [Oncovin], prednisone, and procarbazine hydrochloride) regimen for advanced Hodgkin disease was compared with MOPP alternating with ABVD (doxorubicin hydrochloride [Adriamycin], bleomycin sulfate, vinblastine sulfate, and dacarbazine).